Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes

Virginie Chesnais, Marie-laure Arcangeli, PhD, Caroline Delette, Alice Rousseau, M'boyba Khadija Diop, Andrea Lefevre, Meyling H. Cheok, MSPharm, PhD, Nicolas Chapuis, PharmD, PhD, Laurence Legros, MD PhD, Sophie Raynaud, MD, Lise Willems, MD PhD, Didier Bouscary, MD PhD, Evelyne Lauret, PhD, Olivier A. Bernard, PhD, Olivier Kosmider, MD PhD, Francoise Pflumio, PhD, Michaela Fontenay, MD PhD

Blood (2016) 128 (22): 3153.

https://doi.org/10.1182/blood.V128.22.3153.3153

Published: 2016

Journal Articles

Gene Expression and Alternative Splicing Datasets Analyses of MDS with Ring Sideroblasts Highlight Alternative Branchpoint Usage in Genes Involved in Iron Metabolism and Erythropoiesis

Abderrahmane Bousta, Sabrina Bondu, Alexandre Houy, Nicolas Cagnard, Carine Lefevre, Delphine Bernard, PhD, Marc-Henri Stern, MD PhD, Michaela Fontenay, MD PhD, Olivier Kosmider, MD PhD

Blood (2016) 128 (22): 1972.

https://doi.org/10.1182/blood.V128.22.1972.1972

Published: 2016

Journal Articles

Proof of Principle for Mutations Monitoring Using Picoliter-Droplet Digital PCR on DNA and Living Cells: Application to Myelodysplastic Syndromes

Hélène Guermouche, Philippe Nizard, PhD, Heng Lu, PhD, Charles Decraene, Juliette Nectoux, PhD, Pierre Laurent-Puig, PhD, Charlotte Proudhon, PhD, Michaela Fontenay, MD PhD, Valérie Taly, PhD, Olivier Kosmider, MD PhD

Blood (2016) 128 (22): 5515.

https://doi.org/10.1182/blood.V128.22.5515.5515

Published: 2016

Journal Articles

A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM

Blood (2015) 126 (23): 2872.

https://doi.org/10.1182/blood.V126.23.2872.2872

Published: 2015

Journal Articles

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Francoise Solly, MD, Catherine Koering, PhD, Aminetou mint Mohamed, PhD, Delphine Maucort-Boulch, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Pascale Flandrin-Gresta, MDPhD, Lionel Adès, MD PhD, Pierre Fenaux, MD PhD, Olivier Kosmider, MD PhD, Emmanuelle Tavernier-Tardy, MDPhD, Jérôme Cornillon, MD, Denis Guyotat, MDPhD, Lydia Campos, MD PhD, Franck Mortreux, PhD, Eric Wattel, MDPhD

Blood (2015) 126 (23): 2840.

https://doi.org/10.1182/blood.V126.23.2840.2840

Published: 2015

Journal Articles

Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome

Mrinal M. Patnaik, MBBS, Emnet A Wassie, MD, Eric Padron, MD, Francesco Onida, MD, Raphael Itzykson, Terra L Lasho, PhD, Olivier Kosmider, MD PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett Ketterling, MD, Rami S Komrokji, MD, Ayalew Tefferi, MD, Eric Solary

Blood (2014) 124 (21): 4633.

https://doi.org/10.1182/blood.V124.21.4633.4633

Published: 2014

Journal Articles

Molecular and Prognostic Correlates of Cytogenetic Abnormalities in Chronic Myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study

Emnet A Wassie, MD, Raphael Itzykson, Terra L Lasho, PhD, Olivier Kosmider, MD PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett Ketterling, MD, Eric Solary, Ayalew Tefferi, MD, Mrinal M. Patnaik, MBBS

Blood (2014) 124 (21): 412.

https://doi.org/10.1182/blood.V124.21.412.412

Published: 2014

Journal Articles

NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience

Virginie Chesnais, Aline Renneville, Andrea Toma, Veronique Sardnal, Marie Passet, Audrey Gauthier, Jacques Delaunay, MD, Aspasia Stamatoulas, MD, Odile Beyne-Rauzy, MDPhD, Pierre Fenaux, MD PhD, Francois Dreyfus, MD, Claude Preudhomme, PharmD, PhD, Olivier Kosmider, MD PhD, Michaela Fontenay

Blood (2014) 124 (21): 533.

https://doi.org/10.1182/blood.V124.21.533.533

Published: 2014

Journal Articles

Collapse of Ribosome Biogenesis Induces Rapid Erythroblast Differentiation

Anna Raimbault, Celia Floquet, PhD, Boris Guyot, Ulku Cuhadar, Olivier Kosmider, MD PhD, Francois Morle, PhD, Patrick Mayeux, PhD, Michaela Fontenay, MD PhD

Blood (2014) 124 (21): 2671.

https://doi.org/10.1182/blood.V124.21.2671.2671

Published: 2014

Journal Articles

ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients

Mrinal M Patnaik, MBBS, Raphael Itzykson, Terra L Lasho, MT, (ASCP), Olivier Kosmider, MD, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Ryan A Knudson, Rhett P Ketterling, Ayalew Tefferi, MD, Eric Solary

Blood (2013) 122 (21): 1510.

https://doi.org/10.1182/blood.V122.21.1510.1510

Published: 2013

Journal Articles

Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).

Blood (2012) 120 (21): 2814.

https://doi.org/10.1182/blood.V120.21.2814.2814

Published: 2012

Journal Articles

Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML)

Raphael Itzykson, Olivier Kosmider, MD, PhD, Aline Renneville, Margot Morabito, Dorothee Buet, Claude Preudhomme, Céline Berthon, MD, PhD, Lionel Ades, MD, PhD, Pierre Fenaux, MD, PhD, Uwe Platzbecker, MD, Olivier Gagey, Philippe Rameau, Francois Delhommeau, PharmD, PHD, Olivier A. Bernard, PhD, Michaela Fontenay, MD, PhD, William Vainchenker, MD, PhD, Nathalie Droin, Ph.D, Eric Solary

Blood (2012) 120 (21): 309.

https://doi.org/10.1182/blood.V120.21.309.309

Published: 2012

Journal Articles

BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes

Blood (2012) 120 (21): 1697.

https://doi.org/10.1182/blood.V120.21.1697.1697

Published: 2012

Journal Articles

Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis

Olivier Kosmider, MD, PhD, Nicolas Chapuis, Sophie Kaltenbach, Romain Coriat, Pascaline boudou-Rouquette, Lise Willems, Virginie Chesnais, Isabelle Radford-Weiss, Valérie Bardet, Patrick Mayeux, Jerome Tamburini, Michaela Fontenay, MD, PhD, Didier Bouscary

Blood (2012) 120 (21): 4786.

https://doi.org/10.1182/blood.V120.21.4786.4786

Published: 2012

Journal Articles

Epigenetic Down-Regulation of NFkB-Mediated FAS Gene Transcription During Progression of Myelodysplastic Syndromes

Sandrine Ettou, Catherine Humbrech, Blandine Benet, Katy Billot, Virginie Mariot, Olivier Kosmider, MD, PhD, Catherine Lacombe, Patrick Mayeux, Eric Solary, Michaela Fontenay, MD, PhD

Blood (2012) 120 (21): 3503.

https://doi.org/10.1182/blood.V120.21.3503.3503

Published: 2012

Journal Articles

NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)

Blood (2012) 120 (21): 3835.

https://doi.org/10.1182/blood.V120.21.3835.3835

Published: 2012

Journal Articles

Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML)

Raphael Itzykson, Olivier Kosmider, MD, PhD, Aline Renneville, Margot Morabito, Céline Berthon, MD, PhD, Lionel Ades, MD, PhD, Pierre Fenaux, MD, PhD, Odile Beyne-Rauzy, MD, PhD, Thorsten Braun, Francois Dreyfus, Nicholas C.P. Cross, PhD, Claude Preudhomme, Olivier A. Bernard, PhD, Michaela Fontenay, MD, PhD, William Vainchenker, MD, PhD, Nathalie Droin, Ph.D, Eric Solary

Blood (2012) 120 (21): 3811.

https://doi.org/10.1182/blood.V120.21.3811.3811

Published: 2012

Journal Articles

Effector CD4 + CD45RA − CD25 bright Foxp3 bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status.

Thorsten Braun, Makoto Miyara, Raphael Itzykson, Aline Renneville, Olivier Kosmider, MD, PhD, Claude Gardin, Eric Solary, Guy Gorochov, Pierre Fenaux, Lionel Ades, MD, PhD

Blood (2012) 120 (21): 2808.

https://doi.org/10.1182/blood.V120.21.2808.2808

Published: 2012

NARROW

Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes

Gene Expression and Alternative Splicing Datasets Analyses of MDS with Ring Sideroblasts Highlight Alternative Branchpoint Usage in Genes Involved in Iron Metabolism and Erythropoiesis

Proof of Principle for Mutations Monitoring Using Picoliter-Droplet Digital PCR on DNA and Living Cells: Application to Myelodysplastic Syndromes

A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome

Molecular and Prognostic Correlates of Cytogenetic Abnormalities in Chronic Myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study

NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience

Collapse of Ribosome Biogenesis Induces Rapid Erythroblast Differentiation

ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients

Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).

Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML)

BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes

Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis

Epigenetic Down-Regulation of NFkB-Mediated FAS Gene Transcription During Progression of Myelodysplastic Syndromes

NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)

Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML)

Effector CD4 + CD45RA − CD25 bright Foxp3 bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only